Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Orchid Pharma Limited (ORCHPHARMA) Stock Price & Analysis

0 Followers

ORCHPHARMA Stock Chart & Stats

₹857.50-₹10.95(-1.26%)
At close: 3:30 PM GMT+5:30
₹800₹900₹1K₹1.1KAug 17Aug 31Sep 15Sep 28Oct 12Oct 26Nov 9
Day’s Range
INR 856.15 - INR 875.10
52-Week Range
INR 471.30 - INR 1,142.65
Previous Close
INR 868.45
Volume
N/A
Average Volume (3M)
4,244
Market Cap
INR 52.01B
Enterprise Value
INR 26.49B
Total Cash (Recent Filing)
INR 832.11M
Total Debt (Recent Filing)
INR 0
Price to Earnings (P/E)
501.6
Beta
1.05
Next Earnings
Nov 14, 2026 (Est.)
EPS Estimate
2.5
Last Dividend Ex-Date
Sep 13, 2012
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

A conservatively financed balance sheet gives Orchid Pharma greater resilience through operating volatility and preserves flexibility for investment, working-capital needs, or other corporate priorities. Growing equity and assets further support its capacity to sustain operations without relying excessively on external borrowing.

Profitability Recovery

The shift from losses to sustained profitability across FY2023–FY2025 indicates that Orchid Pharma has established a stronger earnings base than earlier in the period. If preserved, this improvement can support internal reinvestment, strengthen financial resilience, and improve long-term operating credibility.

Multi-year Revenue Expansion

Strong revenue expansion over FY2022–FY2025 demonstrates that Orchid Pharma has previously been able to grow its business meaningfully across multiple years. Although the latest decline is a concern, the earlier trajectory provides evidence of commercial scale-up and a foundation that can support renewed growth.

Bears Say

FY2026 Earnings Deterioration

The FY2026 revenue contraction and sharp operating-profit decline weaken confidence in near-term earnings durability. Continued margin pressure or weaker demand could reduce the company’s ability to compound profits, fund expansion internally, and convert its earlier profitability improvement into a consistently stronger earnings profile.

Negative Free Cash Flow

Recurring negative free cash flow indicates that accounting profitability has not consistently translated into cash available for reinvestment, debt reduction, or shareholder returns. The large FY2026 outflow may reflect heavy investment spending or working-capital needs, reducing financial flexibility if the pattern persists.

Operating Cash-flow Volatility

Wide swings in operating cash flow make Orchid Pharma’s cash generation less predictable and complicate long-term capital planning. Even with periods of strong inflow, recurring weak years can constrain funding for growth and increase reliance on balance-sheet resources when operating conditions soften.

Orchid Pharma Limited News

ORCHPHARMA FAQ

What was Orchid Pharma Limited’s price range in the past 12 months?
Orchid Pharma Limited lowest stock price was ₹471.30 and its highest was ₹1142.65 in the past 12 months.
What is Orchid Pharma Limited’s market cap?
Orchid Pharma Limited’s market cap is ₹52.01B.
When is Orchid Pharma Limited’s upcoming earnings report date?
Orchid Pharma Limited’s next earnings report is estimated for Nov 14, 2026 (not yet confirmed), which is in 1 day.
How were Orchid Pharma Limited’s earnings last quarter?
Orchid Pharma Limited released its earnings results on Aug 14, 2026. The company reported ₹0.636 earnings per share for the quarter, missing the consensus estimate of ₹3.6 by -₹2.964.
Is Orchid Pharma Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Orchid Pharma Limited pay dividends?
Orchid Pharma Limited pays an annual dividend of ₹3 which represents an annual dividend yield of ―. See more information on Orchid Pharma Limited dividends here
What is Orchid Pharma Limited’s EPS estimate?
Orchid Pharma Limited’s EPS estimate is 2.50.
How many shares outstanding does Orchid Pharma Limited have?
Orchid Pharma Limited has 59,885,200 shares outstanding.
What happened to Orchid Pharma Limited’s price movement after its last earnings report?
Orchid Pharma Limited reported an EPS of ₹0.636 in its last earnings report, missing expectations of ₹3.6. Following the earnings report the stock price went up 1.316%.
Which hedge fund is a major shareholder of Orchid Pharma Limited?
Currently, no hedge funds are holding shares in IN:ORCHPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology